Cassava Sciences (SAVA) said Monday that simufilam reduced seizure frequency in a mouse model of tuberous sclerosis complex-related epilepsy.
The company said the mice were treated with multiple doses of simufilam and seizure activity was monitored for three weeks.
According to the company, the drug candidate attenuated the progression of seizure activity with a statistically significant correlation between simufilam dose and the number of seizures.
A first clinical study is expected to begin in H1 2026, the company said.
Shares of Cassava Sciences rose more than 3% in recent premarket activity Monday.
Price: 2.20, Change: +0.08, Percent Change: +3.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。